158 related articles for article (PubMed ID: 32385013)
1. Meta-Analysis Treatment Hyperphosphatemia Chronic Renal Failure Based on Nano Lanthanum Hydroxide.
Jiang M; Zheng H; Xu C; Wang Y; Wan T
J Nanosci Nanotechnol; 2020 Oct; 20(10):6555-6560. PubMed ID: 32385013
[TBL] [Abstract][Full Text] [Related]
2. Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
Guo H; Zhang X; Tang S; Zhang S
Ren Fail; 2013; 35(10):1455-64. PubMed ID: 23992043
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Joy MS; Finn WF;
Am J Kidney Dis; 2003 Jul; 42(1):96-107. PubMed ID: 12830461
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis--a systematic review and meta-analysis of randomized controlled trials.
Huang W; Liu J; Tang Y; Gao X; Di B; Zhang F
Curr Med Res Opin; 2014 Jan; 30(1):99-108. PubMed ID: 24063635
[TBL] [Abstract][Full Text] [Related]
5. Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Ogata H; Fukagawa M; Hirakata H; Kagimura T; Fukushima M; Akizawa T;
JAMA; 2021 May; 325(19):1946-1954. PubMed ID: 34003226
[TBL] [Abstract][Full Text] [Related]
6. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
Chiang SS; Chen JB; Yang WC
Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
[TBL] [Abstract][Full Text] [Related]
7. Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Lee YK; Choi HY; Shin SK; Lee HY
Clin Nephrol; 2013 Feb; 79(2):136-42. PubMed ID: 23211335
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
Zhao L; Liu A; Xu G
Ren Fail; 2021 Dec; 43(1):1378-1393. PubMed ID: 34602015
[TBL] [Abstract][Full Text] [Related]
9. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Shigematsu T;
Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
[TBL] [Abstract][Full Text] [Related]
10. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
Sprague SM; Abboud H; Qiu P; Dauphin M; Zhang P; Finn W
Clin J Am Soc Nephrol; 2009 Jan; 4(1):178-85. PubMed ID: 19056618
[TBL] [Abstract][Full Text] [Related]
11. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
12. Effect of lanthanum carbonate on the progression of coronary artery calcification in hemodialysis patients: A meta-analysis of randomized controlled trials.
Xu JP; Zeng RX; Liao PD; Zhang MZ
Hemodial Int; 2022 Apr; 26(2):223-233. PubMed ID: 34897963
[TBL] [Abstract][Full Text] [Related]
13. One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Shigematsu T;
Ther Apher Dial; 2010 Feb; 14(1):12-9. PubMed ID: 20438515
[TBL] [Abstract][Full Text] [Related]
14. Nano-lanthanum hydroxide, a novel phosphate binder, for treating hyperphosphatemia: A preclinical study.
Ma Z; Yu T; Wu Y; Liu D; Zhang X; Miao X; Xing H; Li G
Biomed Pharmacother; 2019 Mar; 111():909-916. PubMed ID: 30841470
[TBL] [Abstract][Full Text] [Related]
15. Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
Shigematsu T; Negi S;
Nephrol Dial Transplant; 2012 Mar; 27(3):1050-4. PubMed ID: 21771755
[TBL] [Abstract][Full Text] [Related]
16. Multicenter study of long-term (two-year) efficacy of lanthanum carbonate.
Ando R; Kimura H; Sato H; Iwamoto S; Yoshizaki Y; Chida Y; Ishida Y; Takayama M; Yamada K; Tachibana K; Ohtsuka M; Kikuchi K; Inoue A
Ther Apher Dial; 2013 Apr; 17 Suppl 1():2-8. PubMed ID: 23586506
[TBL] [Abstract][Full Text] [Related]
17. Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials.
Wang F; Lu X; Zhang J; Xiong R; Li H; Wang S
Kidney Blood Press Res; 2018; 43(2):536-544. PubMed ID: 29627829
[TBL] [Abstract][Full Text] [Related]
18. Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
Vemuri N; Michelis MF; Matalon A
BMC Nephrol; 2011 Sep; 12():49. PubMed ID: 21962172
[TBL] [Abstract][Full Text] [Related]
19. Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
Ando R; Yama S; Ohnishi T; Iwamoto S; Kimura H; Chida Y; Ishida Y; Yamada K; Inagaki Y; Takayama M; Tachibana K; Kikuchi K; Inoue A; Ohtsuka M
Ther Apher Dial; 2014 Jun; 18 Suppl 1():2-8. PubMed ID: 24953759
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Shigematsu T; Ohya M; Negi S; Masumoto AR; Nakashima YM; Iwatani Y; Moribata MK; Yamanaka S; Tatsuta K; Mima T
Contrib Nephrol; 2015; 185():42-55. PubMed ID: 26023014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
